CN113842400A - 一种含有水飞蓟提取物和后生元的组合物及其在护肝中的应用 - Google Patents
一种含有水飞蓟提取物和后生元的组合物及其在护肝中的应用 Download PDFInfo
- Publication number
- CN113842400A CN113842400A CN202111067964.4A CN202111067964A CN113842400A CN 113842400 A CN113842400 A CN 113842400A CN 202111067964 A CN202111067964 A CN 202111067964A CN 113842400 A CN113842400 A CN 113842400A
- Authority
- CN
- China
- Prior art keywords
- extract
- silybum marianum
- composition
- marianum extract
- lactobacillus plantarum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 241001465754 Metazoa Species 0.000 title abstract description 18
- 210000004185 liver Anatomy 0.000 title description 9
- 235000010841 Silybum marianum Nutrition 0.000 claims abstract description 73
- 244000272459 Silybum marianum Species 0.000 claims abstract description 72
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 34
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 34
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 34
- 239000003094 microcapsule Substances 0.000 claims abstract description 3
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims description 33
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims description 28
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 claims description 20
- CYGIJEJDYJOUAN-UHFFFAOYSA-N Isosilychristin Natural products C1=C(O)C(OC)=CC(C2C3C=C(C4C(C3=O)(O)OCC42)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 CYGIJEJDYJOUAN-UHFFFAOYSA-N 0.000 claims description 15
- 235000014899 silybin Nutrition 0.000 claims description 13
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 9
- SEBFKMXJBCUCAI-WAABAYLZSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2s,3s)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-WAABAYLZSA-N 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 8
- 239000002502 liposome Substances 0.000 claims description 7
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 claims description 6
- FDQAOULAVFHKBX-HKTJVKLFSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2r,3r)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC(=CC=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-HKTJVKLFSA-N 0.000 claims description 5
- QYCJAWYDGRZSTO-IRLTUAEKSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2r,3s)-7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1-benzofuran-4-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](C3=C(C(=CC=C3[C@@H]3[C@H](C(=O)C4=C(O)C=C(O)C=C4O3)O)O)O2)CO)=C1 QYCJAWYDGRZSTO-IRLTUAEKSA-N 0.000 claims description 5
- FDQAOULAVFHKBX-WAABAYLZSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2s,3s)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](OC3=CC(=CC=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-WAABAYLZSA-N 0.000 claims description 5
- FDQAOULAVFHKBX-MNPDLOSFSA-N Isosilybin B Natural products C1=C(O)C(OC)=CC([C@@H]2[C@@H](OC3=CC(=CC=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-MNPDLOSFSA-N 0.000 claims description 5
- RIAZZJBPJQWPIS-UHFFFAOYSA-N Silychristin Natural products COc1cc(ccc1O)C2OC3C(C=C(C=C3O)C4Oc5cc(O)cc(O)c5C(=O)C4O)C2CO RIAZZJBPJQWPIS-UHFFFAOYSA-N 0.000 claims description 5
- MZBGBHVFCYCYLX-UHFFFAOYSA-N Silydianin Natural products COc1cc(ccc1O)C2C3COC4(O)C3C=C(C5Oc6cc(O)cc(O)c6C(=O)C5O)C2C4=O MZBGBHVFCYCYLX-UHFFFAOYSA-N 0.000 claims description 5
- 235000015872 dietary supplement Nutrition 0.000 claims description 5
- BMLIIPOXVWESJG-LMBCONBSSA-N silychristin Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](C3=C(C(=CC(=C3)[C@@H]3[C@H](C(=O)C4=C(O)C=C(O)C=C4O3)O)O)O2)CO)=C1 BMLIIPOXVWESJG-LMBCONBSSA-N 0.000 claims description 5
- BMLIIPOXVWESJG-UHFFFAOYSA-N silychristin A Natural products C1=C(O)C(OC)=CC(C2C(C3=C(C(=CC(=C3)C3C(C(=O)C4=C(O)C=C(O)C=C4O3)O)O)O2)CO)=C1 BMLIIPOXVWESJG-UHFFFAOYSA-N 0.000 claims description 5
- CYGIJEJDYJOUAN-JSGXPVSSSA-N silydianin Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@H]3C=C([C@@H]4[C@@](C3=O)(O)OC[C@@H]42)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 CYGIJEJDYJOUAN-JSGXPVSSSA-N 0.000 claims description 5
- FDQAOULAVFHKBX-KMRPREKFSA-N (+)-Isosilybin A Natural products C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC(=CC=C3O2)[C@@H]2[C@@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-KMRPREKFSA-N 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- -1 thioalkyl lipid Chemical class 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 235000013406 prebiotics Nutrition 0.000 claims description 2
- 229950000628 silibinin Drugs 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000002929 anti-fatigue Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 9
- 206010067125 Liver injury Diseases 0.000 abstract description 8
- 231100000753 hepatic injury Toxicity 0.000 abstract description 8
- 208000006454 hepatitis Diseases 0.000 abstract description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 description 31
- 229920006008 lipopolysaccharide Polymers 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 26
- 241000894006 Bacteria Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229940043175 silybin Drugs 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000000683 abdominal cavity Anatomy 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 6
- 229960004245 silymarin Drugs 0.000 description 6
- 235000017700 silymarin Nutrition 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 208000018191 liver inflammation Diseases 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000320380 Silybum Species 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Psychiatry (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种组合物,组合物含有水飞蓟提取物和后生元;水飞蓟提取物可以为水飞蓟提取物微胶囊形式,后生元可以选择为灭活的植物乳杆菌L137,后生元可以调节肠道菌群平衡,修复肠道,减少肠漏降低对肝炎的诱因,水飞蓟提取物与后生元的组合具有减少肝损伤的功效。
Description
技术领域
本发明涉及一种组合物,具体涉及减少肝损伤等效果的组合物及其应 用。
背景技术
水飞蓟,又名奶蓟草,原产于地中海地区,其作为药用植物使用已经 有接近两千年的历史,至今仍作为一种非常有效的护肝植物被广泛使用。 它可以帮助肝脏解毒,也可以用于控制慢性肝脏疾病。水飞蓟能激活肝脏 蛋白的再生,恢复被酒精和病毒所破坏的肝细胞的活性,还可清除自由 基、维持肝脏细胞膜的通透性,降低毒素对肝脏的损伤,保护长期饮酒伤 肝和患有急慢性肝炎、脂肪肝、肝硬化和中毒性肝损害的人群。
水飞蓟提取物以水飞蓟Silybummarianum的干燥果实为原料,商品提取 物通常标化为含总水飞蓟素80%。水飞蓟素是多酚类的复杂混合物,包括 七种关系密切的黄酮醇-木质素加成物(水飞蓟宾A、水飞蓟宾B、异水飞 蓟宾A、异水飞蓟宾B、水飞蓟亭、异水飞蓟亭及水飞蓟宁)和一种类黄 酮黄杉素(taxifolin)。水飞蓟宾是水飞蓟素的半纯化部分,主要是两种 非对映异构体(水飞蓟宾A和水飞蓟宾B)的混合物。
当我们处于健康状态时,小肠肠壁只允许营养物质穿过肠壁进入血 液,通过血液循环流到身体所需的其它部位。其它不允许进入的物质一律 被拒之门外。肠壁细胞与细胞之间通过紧密连接结合在一起,然而,这种 紧密连接很容易受到破坏,如肥胖,慢性疲劳,菌群失调等。
对于压力大,肥胖,代谢失调,肠道紊乱等的亚健康人群,肠道细胞 和紧密连接蛋白被破坏,细胞与细胞之间的间隙就会变得更大,使得来源 于微生物或食物的脂多糖穿过肠壁,与脂蛋白绑定进入肝脏循环,从而导 致肝脏炎症。对亚健康人群,单纯补充抗菌抗炎抗氧化的补充剂如水飞蓟 只能减少已经在发生的炎症,对于外部入侵的脂多糖等导致的肝脏炎症无 法起到保护作用。
本发明将水飞蓟与后生元组合在一起,从而起到对肝脏疾病的预防和 治愈的作用。
发明内容
本发明的目的在于针对现有技术的不足之处,提供一种组合物,含有 水飞蓟提取物和后生元。
进一步的,水飞蓟提取物包括水飞蓟宾A、水飞蓟宾B、异水飞蓟宾 A、异水飞蓟宾B、水飞蓟亭、异水飞蓟亭、水飞蓟宁、黄杉素中的一种 或多种;进一步优选的,水飞蓟提取物包括水飞蓟宾A和其他类型水飞蓟 提取物的组合。
进一步的,水飞蓟提取物为水飞蓟提取物微胶囊形式和/或水飞蓟提 取物脂质体形式和/或水飞蓟提取物自微乳化形式,优选为水飞蓟提取物- 磷脂的形式、水飞蓟提取物-磷脂-胆固醇的形式、水飞蓟提取物-环糊精的 形式的一种或多种。
进一步优选为水飞蓟提取物-磷脂-胆固醇的脂质体形式和水飞蓟提取 物-磷脂复合物的形式复配,或为飞蓟提取物-磷脂-胆固醇的脂质体形式和 水飞蓟提取物-环糊精的形式复配。
进一步的,所述后生元为死菌体,或为包含活菌体和死菌体。优选为 至少含有死菌体。死菌体和活菌体的组合中,死菌体与活菌体的比例为 99:1、95:5、90:10、80:20、75:25、60:40、50:50、40:60、30:70、20:80、 10:90、1:99。
进一步的,后生元含有菌体和菌体的代谢产物。
进一步的,后生元为植物乳杆菌制成的后生元。
进一步的,植物乳杆菌为植物乳杆菌L137。
进一步的,植物乳杆菌为L-137的死菌体。
进一步的,组合物中水飞蓟提取物含量为1-99.9%(w/w),优选为 10-99.5%(w/w),进一步优选为90-99%(w/w);植物乳杆菌为0.01- 99%(w/w),优选为0.05-90%(w/w),进一步优选为1-10%(w/w)。
进一步的,水飞蓟提取物中的水飞蓟宾(水飞蓟宾A和水飞蓟宾B) 占水飞蓟宾A、水飞蓟宾B、异水飞蓟宾A、异水飞蓟宾B、水飞蓟亭、 异水飞蓟亭、水飞蓟宁、黄杉素总含量的20%以上,具有为30%以上、 40%以上、50%以上、60%以上、70%以上、80%以上、90%以上、95%以 上、96%以上、97%以上、98%以上、99%以上或100%。
水飞蓟提取物的纯度为50%以上,具有60%以上、70%以上、80%以 上、90%以上、95%以上、96%以上、97%以上、98%以上、99%以上或 100%。
进一步所述死菌体,灭活方式可以为加热、紫外辐照、化学处理;优 选为热灭活菌体。所述热灭活菌体可以为在培养结束后,收集菌体后制备 加热死菌体,或者也可以不将菌体从培养液中暂时分离,而是将培养液中 的菌体制成加热死菌体,然后采集该加热死菌体。植物乳杆菌L-137的加 热死菌体加热温度通常约为60~100℃,优选约为70~90℃,作为加热手 段,可以为使用加热器的公知手段。在达到所需温度后,加热时间通常约 为5~40分钟,优选约为10~30分钟。
死菌体可进一步进行研磨、破碎或冻结干燥处理等,从而制成死菌体 处理物。在本发明中,所述死菌体处理物也可适宜地用作死菌体。
本发明中死菌体的形态可以为糊状形态、悬浊液形态、乳状形态、粉 状形态、颗粒形态,优选为粉末形态。
本发明中死菌体的数量为其活菌的数量灭活后的死菌体数量。因死菌 体数量的检测手段的有限性,本发明中,死菌体的菌体数量可由对生产该 死菌体的活菌活菌数、活菌密度进行检测而推算确定。
进一步的,组合物中包含或者不包含填充剂/载体,组合物中的植物 乳杆菌用量为0.5亿/g-500亿/g,进一步1亿/g-100亿/g,进一步10亿/g- 50亿/g,进一步20亿/g-30亿/g。
进一步的,组合物中还含有谷胱甘肽。
本发明还提供了一种产品,包括上述组合物,所述产品剂型为注射 液、口服液、片剂、硬胶囊、软胶囊、糖果、固体饮料、液体饮料、膏滋 中的一种。
进一步的,所述产品还包括辅料;其中辅料包括:水、赋形剂、色 素、甜味剂、pH调节剂、增稠剂、粘合剂、崩解剂、填充剂。
本发明还提供了组合物在肝损伤类药品、保健食品、膳食补充剂和食 品中的应用;
或/和在护肝类药品、保健食品、膳食补充剂和食品中的应用。
术语解释
本文所用的“抗”,在没有特别说明的情况下,包含有预防、抑制、清 除的效果。
本文所用的“肝损伤”,在没有特别说明的情况下,包含有物理、化 学、生物等方式带来的损伤。
本文所用的“死菌体”,在没有特别说明的情况下,为灭活的菌体。
本文所用的“后生元”,为益生菌经加工处理后的益菌成分统称,包 括菌体与代谢产物。
本文所用的“L137”,在没有特别说明的情况下,为灭活的植物乳杆 菌L137。
附图说明:
图1为护肝效果动物试验1的ALT的试验情况;
图2为护肝效果动物试验2的AST的试验情况。
具体实施方式
为了便于本领域技术人员的理解,下面结合实施例对本发明作进一步 的说明,实施方式提及的内容并非对本发明的限定。
实施例1
一种组合物,含有水飞蓟提取物和灭活的植物乳杆菌L137,水飞蓟 提取物中水飞蓟宾(包括水飞蓟宾A和水飞蓟宾B)占水飞蓟提取物的 80%,水飞蓟提取物为水飞蓟-磷脂复合物的形式,水飞蓟提取物为40% (w/w),灭活的植物乳杆菌L137为60%(w/w)。
实施例2
一种组合物,含有水飞蓟提取物和灭活的植物乳杆菌L137,水飞蓟 提取物中水飞蓟宾占水飞蓟提取物的70%,水飞蓟提取物为20% (w/w),灭活的植物乳杆菌L137为80%(w/w)。
实施例3
一种组合物,含有水飞蓟提取物和灭活的植物乳杆菌L137和活的植 物乳杆菌,水飞蓟提取物中水飞蓟宾占水飞蓟提取物的90%,水飞蓟提取 物为33.3%(w/w),植物乳杆菌为66.7%(w/w)。
实施例4
一种组合物,含有水飞蓟提取物和灭活的植物乳杆菌L137,水飞蓟 提取物中水飞蓟宾占水飞蓟提取物的80%,水飞蓟提取物为40% (w/w),灭活的植物乳杆菌L137为40%(w/w),谷胱甘肽为20% (w/w)。
实施例5
一种组合物,含有水飞蓟提取物和灭活的植物乳杆菌L137,水飞蓟 提取物中水飞蓟宾占水飞蓟提取物的80%,水飞蓟提取物为99% (w/w),灭活的植物乳杆菌L137为1%(w/w)。
实施例6
一种组合物,含有水飞蓟提取物和灭活的植物乳杆菌L137,水飞蓟 提取物中水飞蓟宾占水飞蓟提取物的80%,水飞蓟提取物为10% (w/w),灭活的植物乳杆菌L137为90%(w/w)。
实施例7
一种胶囊,含有水飞蓟提取物和灭活的植物乳杆菌L137,水飞蓟提 取物中水飞蓟宾占水飞蓟提取物的80%,水飞蓟提取物为0.12g,灭活的 植物乳杆菌L137为2.4mg。
实施例8
一种胶囊,含有水飞蓟提取物和灭活的植物乳杆菌L137,水飞蓟提 取物中水飞蓟宾占水飞蓟提取物的80%,水飞蓟提取物为水飞蓟提取物- 磷脂-胆固醇脂质体的形式,水飞蓟提取物为0.06g,灭活的植物乳杆菌 L137为1.2mg。
实施例9
一种胶囊,含有水飞蓟提取物和灭活的植物乳杆菌L137,水飞蓟提 取物中水飞蓟宾占水飞蓟提取物的80%,水飞蓟提取物为0.24g,灭活的 植物乳杆菌L137为4.8mg。
实施例10
一种胶囊,含有水飞蓟提取物和灭活的植物乳杆菌L137,水飞蓟提 取物中水飞蓟宾占水飞蓟提取物的60%,水飞蓟提取物为0.08g,灭活的 植物乳杆菌L137为0.8mg。
实验例1
动物:雄性昆明小鼠(20±2g):将小鼠置于动物实验室,室温培养。分 笼饲养。
护肝效果动物试验1:
分组:取50只小鼠随机平均分为5组,即为:控制组、脂多糖组 (肝脏损伤组)、脂多糖+水飞蓟组、脂多糖+L137组、脂多糖+水飞蓟 +L137组。
控制组:饲料+生理盐水填喂15天,腹腔注射生理盐水。
脂多糖组(肝脏损伤组):饲料+生理盐水填喂15天,腹腔注射4mg/kg Escherichiacoli脂多糖。
脂多糖+水飞蓟组:饲料+75mg/kg水飞蓟素+生理盐水填喂15天,腹 腔注射4mg/kgEscherichia coli脂多糖。
脂多糖+L137组:饲料+1.5mg/kg L137+生理盐水填喂15天,腹腔注 射4mg/kgEscherichia coli脂多糖。
脂多糖+水飞蓟+L137组:饲料+75mg/kg+1.5mg/kg L137+生理盐水填喂15 天,腹腔注射4mg/kg Escherichia coli脂多糖。
结食12小时后,取小鼠血样,在3000X g,4摄氏度的条件下离心分 离15分钟,取上层澄清液测试。丙氨酸转氨酶ALT和天冬氨酸转氨酶 AST用756P紫外-可见光分光光度计测试。
表1护肝效果动物试验1的ALT和AST的试验情况
ALT(IU/L) | AST(IU/L) | |
控制组 | 48.4±5.1 | 75.5±8.6 |
脂多糖组(模型组) | 102.3±10.7, | 169.7±19.3, |
脂多糖+水飞蓟 | 85.7±9.4,p<0.05 | 127.7±15.9,p<0.05 |
脂多糖+L137 | 95.1±9.8,p<0.05 | 159.2±13.1,p<0.05 |
脂多糖+水飞蓟+L137 | 69.6±7.4,p<0.05 | 108.8±12.3,p<0.05 |
由数据可知,相比于脂多糖组,L137组血清ALT,AST有所降低, 水飞蓟,及水飞蓟+L137组的保护作用下的血清ALT,AST均有显著降 低。水飞蓟+L137组合物的降低的数值要好于单独的水飞蓟或L137。
说明日常服用水飞蓟+L137的小鼠,对脂多糖等毒素导致的肝脏发炎 有更强的抵抗力。水飞蓟提取物可以优化线粒体代谢,减少细胞内的活性 氧水平,降低NF-κB表达;而L137通过阻断TLR4 mRNA,从而影响 TLR4-NF-κB通路,抑制肝脏中NF-κB表达,对NF-κB降低起到增强 作用,从而能够增强了水飞蓟的抗炎效果。
实验例2
40只957-992g雄性新西兰白兔,其中10只作为为控制组;
控制组:每日饲料+生理盐水填喂,腹腔注射生理盐水,持续两周。
脂多糖组(模型组):每日饲料+生理盐水填喂,腹腔注射5mcg/kg Escherichiacoli脂多糖,持续两周。
造模结束后,在3000X g,4摄氏度的条件下离心分离15分钟,取上 层澄清液。丙氨酸转氨酶ALT和天冬氨酸转氨酶AST用756P紫外-可 见光分光光度计测试。
控制组:继续喂食每日饲料+生理盐水填喂,持续六周。
将模型组分为三组,分别作为baseline。
脂多糖+L-137组:每日饲料+0.5mg/kg L137+生理盐水填喂,腹腔注 射0.5mcg/kg脂多糖,持续六周。
脂多糖+水飞蓟组:每日饲料+25mg/kg水飞蓟素+生理盐水填喂,腹 腔注射0.5mcg/kg脂多糖,持续六周。
脂多糖+水飞蓟+L137组:每日饲料+25mg/kg水飞蓟素+0.5mg/kg L137+生理盐水填喂,腹腔注射0.5mcg/kg脂多糖,持续六周。
每周取兔子血样,在3000X g,4摄氏度的条件下离心分离15分钟, 取上层澄清液测试。丙氨酸转氨酶ALT和天冬氨酸转氨酶AST用756P 紫外-可见光分光光度计测试。
表2护肝效果动物试验2的ALT的试验情况
表3护肝效果动物试验2的AST的试验情况
由表2-3和图2可知,对于脂多糖导致的肝脏发炎且存在外源脂多糖 干扰的情况下,使用水飞蓟+L137的兔子,曲线斜率更高,即能更快的降 低炎症,更快见效。原因一方面,因此L137影响代谢通路进而影响水飞 蓟的抗炎效果,另一方面,L137对肠道菌群的调节作用有利于修复肠 漏,减少外源性脂多糖透过肠道进入循环系统,对肝脏造成损伤。同时水 飞蓟本身对肝脏具有消炎抗菌的作用,组合物起到了内外协同的保护作 用。
本技术领域技术人员可以理解,除非另外定义,这里使用的所有术语 (包括技术术语和科学术语),具有与本发明所属领域中的普通技术人员的 一般理解相同的意义。还应该理解的是,诸如通用字典中定义的那些术 语,应该被理解为具有与现有技术的上下文中的意义一致的意义,并且除 非像这里一样被特定定义,否则不会用理想化或过于正式的含义来解释。
应当理解,以上借助优选实施例对本发明的技术方案进行的详细说明 是示意性的而非限制性的。本领域的普通技术人员在阅读本发明说明书的 基础上可以对各实施例所记载的技术方案进行修改,或者对其中部分技术 特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱 离本发明各实施例技术方案的精神和范围。
Claims (9)
1.一种组合物,其特征在于:含有水飞蓟提取物和后生元。
2.根据权利要求1所述组合物,其特征在于:水飞蓟提取物包括水飞蓟宾A、水飞蓟宾B、异水飞蓟宾A、异水飞蓟宾B、水飞蓟亭、异水飞蓟亭、水飞蓟宁、黄杉素中的一种或多种;
和/或
水飞蓟宾A、水飞蓟宾B、异水飞蓟宾A、异水飞蓟宾B、水飞蓟亭、异水飞蓟亭、水飞蓟宁、黄杉素的衍生物的一种或多种;优选为硫代烷基脂类衍生物。
3.根据权利要求1所述组合物,其特征在于:水飞蓟提取物为水飞蓟提取物微胶囊形式和/或水飞蓟提取物脂质体形式和/或水飞蓟提取物自微乳化形式,优选为水飞蓟提取物-磷脂的形式、水飞蓟提取物-磷脂-胆固醇的形式、水飞蓟提取物-环糊精的形式的一种或多种;进一步优选为水飞蓟提取物-磷脂-胆固醇的脂质体形式和水飞蓟提取物-磷脂复合物的形式复配,或为飞蓟提取物-磷脂-胆固醇的脂质体形式和水飞蓟提取物-环糊精的形式复配。
4.根据权利要求1的所述组合物,其特征在于:后生元为植物乳杆菌制成的后生元;进一步的,为植物乳杆菌L137。
5.根据权利要求1的所述组合物,其特征在于:组合物中水飞蓟提取物含量为1-99.9%(w/w),优选为10-99.5%(w/w),进一步优选为90-99%(w/w);植物乳杆菌为0.01-99%(w/w),优选为0.05-90%(w/w),进一步优选为1-10%(w/w);
和/或,组合物中包含或者不包含填充剂/载体,组合物中的植物乳杆菌用量为0.5亿/g-500亿/g,进一步1亿/g-100亿/g,进一步10亿/g-50亿/g,进一步20亿/g-30亿/g。
6.根据权利要求1的所述组合物,其特征在于:水飞蓟提取物中的水飞蓟宾占水飞蓟提取物的量为20%以上,优选为30%以上、40%以上、50%以上、60%以上、70%以上、80%以上、90%以上、95%以上、96%以上、97%以上、98%以上、99%以上或100%。
7.一种产品,包括权利要求1-6之一的所述组合物,所述产品剂型为注射液、口服液、片剂、硬胶囊、软胶囊、糖果、固体饮料、液体饮料、膏滋中的一种。
8.根据权利要求7所述的产品,其特征在于,还包括辅料;其中辅料包括:水、赋形剂、色素、甜味剂、pH调节剂、增稠剂、粘合剂、崩解剂、填充剂。
9.权利要求1-6之一的所述组合物、权利要求7、8所述的产品,在护肝类药品、保健食品、膳食补充剂和/或食品中的应用;
或/和在抗疲劳类的药品、保健食品、膳食补充剂和/或食品中的应用;
或/和在抗抑郁和抗焦虑的药品、保健食品、膳食补充剂和/或食品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111067964.4A CN113842400A (zh) | 2021-09-13 | 2021-09-13 | 一种含有水飞蓟提取物和后生元的组合物及其在护肝中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111067964.4A CN113842400A (zh) | 2021-09-13 | 2021-09-13 | 一种含有水飞蓟提取物和后生元的组合物及其在护肝中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113842400A true CN113842400A (zh) | 2021-12-28 |
Family
ID=78973929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111067964.4A Pending CN113842400A (zh) | 2021-09-13 | 2021-09-13 | 一种含有水飞蓟提取物和后生元的组合物及其在护肝中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113842400A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114480192A (zh) * | 2022-01-21 | 2022-05-13 | 四川高福记生物科技有限公司 | 一种后生元及其制备方法与应用 |
CN115153010A (zh) * | 2022-06-24 | 2022-10-11 | 广州正明后生元科技有限公司 | 一种后生元护肝解酒片及其制备方法 |
WO2024100755A1 (ja) * | 2022-11-08 | 2024-05-16 | ハウスウェルネスフーズ株式会社 | 腸管バリア機能向上用及び腸管上皮タイトジャンクション増強用組成物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112274547A (zh) * | 2020-11-12 | 2021-01-29 | 南京北极光生物科技有限公司 | 一种含有水飞蓟提取物和1,6二磷酸果糖的组合物及其在护肝、醒酒、抗疲劳中的应用 |
CN112972464A (zh) * | 2021-03-18 | 2021-06-18 | 南京北极光生物科技有限公司 | 一种含有褪黑素和水飞蓟提取物的组合物及其在助眠和护肝上的应用 |
-
2021
- 2021-09-13 CN CN202111067964.4A patent/CN113842400A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112274547A (zh) * | 2020-11-12 | 2021-01-29 | 南京北极光生物科技有限公司 | 一种含有水飞蓟提取物和1,6二磷酸果糖的组合物及其在护肝、醒酒、抗疲劳中的应用 |
CN112972464A (zh) * | 2021-03-18 | 2021-06-18 | 南京北极光生物科技有限公司 | 一种含有褪黑素和水飞蓟提取物的组合物及其在助眠和护肝上的应用 |
Non-Patent Citations (1)
Title |
---|
YUSUKE TANAKA等: "Daily intake of heat-killed Lactobacillus plantarum L-137 improves inflammation and lipid metabolism in overweight healthy adults: a randomized-controlled trial", 《EUROPEAN JOURNAL OF NUTRITION 》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114480192A (zh) * | 2022-01-21 | 2022-05-13 | 四川高福记生物科技有限公司 | 一种后生元及其制备方法与应用 |
CN114480192B (zh) * | 2022-01-21 | 2023-08-22 | 四川高福记生物科技有限公司 | 一种后生元及其制备方法与应用 |
CN115153010A (zh) * | 2022-06-24 | 2022-10-11 | 广州正明后生元科技有限公司 | 一种后生元护肝解酒片及其制备方法 |
WO2024100755A1 (ja) * | 2022-11-08 | 2024-05-16 | ハウスウェルネスフーズ株式会社 | 腸管バリア機能向上用及び腸管上皮タイトジャンクション増強用組成物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Astragali Radix (Huangqi): A promising edible immunomodulatory herbal medicine | |
Roy et al. | Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives | |
CN113842400A (zh) | 一种含有水飞蓟提取物和后生元的组合物及其在护肝中的应用 | |
Batista et al. | Probiotics, prebiotics, synbiotics, and paraprobiotics as a therapeutic alternative for intestinal mucositis | |
Karasawa et al. | A matured fruit extract of date palm tree (Phoenix dactylifera L.) stimulates the cellular immune system in mice | |
Bhushan et al. | Bioactive compounds and probiotics–a ray of hope in COVID-19 management | |
Su et al. | The anti‐obesity and gut microbiota modulating effects of taxifolin in C57BL/6J mice fed with a high‐fat diet | |
CN109419814B (zh) | 戈氏副拟杆菌用于抑制脂肪肝疾病的用途 | |
US20170368135A1 (en) | Herbal drug composition containing probiotic and optionally prebiotic and/or active pharmaceutical ingredient | |
Li et al. | A flavonoid-rich Smilax china L. extract prevents obesity by upregulating the adiponectin-receptor/AMPK signalling pathway and modulating the gut microbiota in mice | |
Zhang et al. | The natural substances with anti-allergic properties in food allergy | |
KR102397916B1 (ko) | 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법 | |
Skinner et al. | Effects of kiwifruit on innate and adaptive immunity and symptoms of upper respiratory tract infections | |
Li et al. | Fermented natural product targeting gut microbiota regulate immunity and anti-inflammatory activity: A possible way to prevent COVID-19 in daily diet | |
Yang et al. | Effects of fenugreek seed extracts on growth performance and intestinal health of broilers | |
Xu et al. | Combination of Houttuynia cordata polysaccharide and Lactiplantibacillus plantarum P101 alleviates acute liver injury by regulating gut microbiota in mice | |
Ahmed et al. | Contemporary evidence on the dynamic role of probiotics in liver diseases. | |
Xue et al. | Preventive and synbiotic effects of the soluble dietary fiber obtained from Lentinula edodes byproducts and Lactobacillus plantarum LP90 against dextran sulfate sodium‐induced colitis in mice | |
RU2506087C2 (ru) | Сиаловая кислота для поддержки иммунной системы в пожилом возрасте | |
Zare et al. | Growth, body proximate composition and selected blood parameters of rainbow trout Onchorhynchus mykiss fingerlings fed on a diet supplemented with nettle Urtica dioica and tarragon Artemisia dracunculus | |
Liu et al. | Paraprobiotic and postbiotic forms of Bacillus siamensis improved growth, immunity, liver and intestinal health in Lateolabrax maculatus fed soybean meal diet | |
Fang et al. | Effect of purple sweet potato-derived anthocyanins on heat stress response in Wenchang chickens and preliminary mechanism study | |
Li et al. | Amelioration of alcohol-induced acute liver injury in C57BL/6 mice by a mixture of TCM phytochemicals and probiotics with antioxidative and anti-inflammatory effects | |
El-Ashram et al. | Effect of basil oil (Ocimum basilicum) on nonspecific immune response of Nile-tilapia (Oreochromis niloticus) | |
Zhao et al. | The attenuating effects of synbiotic containing Cetobacterium somerae and Astragalus polysaccharide against trichlorfon-induced hepatotoxicity in crucian carp (Carassius carassius) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211228 |